Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis.Int J Infect Dis. 2016 Aug; 49:129-33.IJ
Abstract
The Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with life-threatening severe illnesses and a mortality rate of approximately 35%, particularly in patients with underlying comorbidities. A systematic analysis of 637 MERS-CoV cases suggests that diabetes and hypertension are equally prevalent in approximately 50% of the patients. Cardiac diseases are present in 30% and obesity in 16% of the cases. These conditions down-regulate the synthesis of proinflammatory cytokines and impair the host's innate and humoral immune systems. In conclusion, protection against MERS-CoV and other respiratory infections can be improved if public health vaccination strategies are tailored to target persons with chronic disorders.
Links
Publisher Full Text
MeSH
Pub Type(s)
Journal Article
Meta-Analysis
Review
Systematic Review
Language
eng
PubMed ID
27352628
Clinical Trial Links
Citation
Badawi, Alaa, and Seung Gwan Ryoo. "Prevalence of Comorbidities in the Middle East Respiratory Syndrome Coronavirus (MERS-CoV): a Systematic Review and Meta-analysis." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 49, 2016, pp. 129-33.
Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-33.
Badawi, A., & Ryoo, S. G. (2016). Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 49, 129-33. https://doi.org/10.1016/j.ijid.2016.06.015
Badawi A, Ryoo SG. Prevalence of Comorbidities in the Middle East Respiratory Syndrome Coronavirus (MERS-CoV): a Systematic Review and Meta-analysis. Int J Infect Dis. 2016;49:129-33. PubMed PMID: 27352628.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis.
AU - Badawi,Alaa,
AU - Ryoo,Seung Gwan,
Y1 - 2016/06/21/
PY - 2016/04/04/received
PY - 2016/05/19/revised
PY - 2016/06/15/accepted
PY - 2016/6/30/entrez
PY - 2016/6/30/pubmed
PY - 2017/2/6/medline
KW - Cardiovascular diseases
KW - Diabetes mellitus
KW - Middle East respiratory syndrome coronavirus (MERS-CoV)
KW - Obesity
KW - Systematic review
SP - 129
EP - 33
JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
JO - Int. J. Infect. Dis.
VL - 49
N2 - The Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with life-threatening severe illnesses and a mortality rate of approximately 35%, particularly in patients with underlying comorbidities. A systematic analysis of 637 MERS-CoV cases suggests that diabetes and hypertension are equally prevalent in approximately 50% of the patients. Cardiac diseases are present in 30% and obesity in 16% of the cases. These conditions down-regulate the synthesis of proinflammatory cytokines and impair the host's innate and humoral immune systems. In conclusion, protection against MERS-CoV and other respiratory infections can be improved if public health vaccination strategies are tailored to target persons with chronic disorders.
SN - 1878-3511
UR - https://www.unboundmedicine.com/medline/citation/27352628/full_citation
L2 - https://linkinghub.elsevier.com/retrieve/pii/S1201-9712(16)31100-6
DB - PRIME
DP - Unbound Medicine
ER -